512 related articles for article (PubMed ID: 23963888)
1. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.
Parikh SA; Tefferi A
Am J Hematol; 2013 Nov; 88(11):967-74. PubMed ID: 23963888
[TBL] [Abstract][Full Text] [Related]
2. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.
Parikh SA; Tefferi A
Am J Hematol; 2012 Jun; 87(6):610-9. PubMed ID: 22615103
[TBL] [Abstract][Full Text] [Related]
3. Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2016 Jun; 91(6):631-42. PubMed ID: 27185207
[TBL] [Abstract][Full Text] [Related]
4. Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management.
Patnaik MM; Tefferi A
Am J Hematol; 2018 Jun; 93(6):824-840. PubMed ID: 29878489
[TBL] [Abstract][Full Text] [Related]
5. Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management.
Patnaik MM; Tefferi A
Am J Hematol; 2020 Jan; 95(1):97-115. PubMed ID: 31736132
[TBL] [Abstract][Full Text] [Related]
6. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).
Wijermans PW; Rüter B; Baer MR; Slack JL; Saba HI; Lübbert M
Leuk Res; 2008 Apr; 32(4):587-91. PubMed ID: 17881052
[TBL] [Abstract][Full Text] [Related]
8. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.
Patnaik MM; Tefferi A
Am J Hematol; 2024 Jun; 99(6):1142-1165. PubMed ID: 38450850
[TBL] [Abstract][Full Text] [Related]
9. Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2022 Mar; 97(3):352-372. PubMed ID: 34985762
[TBL] [Abstract][Full Text] [Related]
10. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
11. Analyses on clinical characteristic and prognoses of 41 patients with chronic myelomonocytic leukemia in China.
Chen B; Ma Y; Xu X; Wang X; Qin W; Ji M; Lin G
Leuk Res; 2010 Apr; 34(4):458-62. PubMed ID: 19631982
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine.
Adès L; Sekeres MA; Wolfromm A; Teichman ML; Tiu RV; Itzykson R; Maciejewski JP; Dreyfus F; List AF; Fenaux P; Komrokji RS
Leuk Res; 2013 Jun; 37(6):609-13. PubMed ID: 23415110
[TBL] [Abstract][Full Text] [Related]
13. Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update.
McCullough KB; Patnaik MM
Curr Hematol Malig Rep; 2015 Sep; 10(3):292-302. PubMed ID: 26122388
[TBL] [Abstract][Full Text] [Related]
14. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2014 Sep; 89(9):915-25. PubMed ID: 25124313
[TBL] [Abstract][Full Text] [Related]
15. Current management of patients with chronic myelomonocytic leukemia.
Alfonso A; Montalban-Bravo G; Garcia-Manero G
Curr Opin Oncol; 2017 Jan; 29(1):79-87. PubMed ID: 27849645
[TBL] [Abstract][Full Text] [Related]
16. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
Aribi A; Borthakur G; Ravandi F; Shan J; Davisson J; Cortes J; Kantarjian H
Cancer; 2007 Feb; 109(4):713-7. PubMed ID: 17219444
[TBL] [Abstract][Full Text] [Related]
17. Chronic Myelomonocytic Leukemia: Focus on Clinical Practice.
Patnaik MM; Tefferi A
Mayo Clin Proc; 2016 Feb; 91(2):259-72. PubMed ID: 26848006
[TBL] [Abstract][Full Text] [Related]
18. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
Alfonso A; Montalban-Bravo G; Takahashi K; Jabbour EJ; Kadia T; Ravandi F; Cortes J; Estrov Z; Borthakur G; Pemmaraju N; Konopleva M; Bueso-Ramos C; Pierce S; Kantarjian H; Garcia-Manero G
Am J Hematol; 2017 Jul; 92(7):599-606. PubMed ID: 28370097
[TBL] [Abstract][Full Text] [Related]
19. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2011 Dec; 86(12):1017-26. PubMed ID: 22086865
[TBL] [Abstract][Full Text] [Related]
20. Cytopenia, dysplasia, and monocytosis: a precursor to chronic myelomonocytic leukemia or a distinct subgroup? Case reports and review of literature.
Singh ZN; Post GR; Kiwan E; Maddox AM
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):293-7. PubMed ID: 21658659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
